Early-stage funding Sonnest recently secured over $4 million in oversubscribed Series A financing, indicating investor confidence and the potential availability of partner-led funding conversations for clinical advancement and strategic collaborations.

Heart imaging focus Electrast aims to provide rapid, cost-effective perfusion assessment at the point of care without ionizing radiation, presenting a compelling value proposition for cardiology departments, interventional labs, and emergency medicine workflows seeking safer imaging alternatives.

Pre-clinical stage As a pre-clinical medical imaging drug, Sonnest offers early engagement opportunities with academic medical centers, KOLs in cardiology and imaging, and potential pilots that validate perfusion imaging in myocardial contexts.

Resource-light With a lean team (2-10 employees) and a focus on specialized ultrasound contrast activation, partnerships with contract research organizations, CROs, or white-label clinical support providers could accelerate development and field adoption.

Tech-forward branding Existing tech stack including WordPress and essential SEO/UX tooling suggests readiness for content-led outreach, thought leadership, and targeted campaigns to cardiology and radiology audiences, complemented by investor and partner communications.